FDA Imposes Partial Hold on Gilead's Magrolimab Trials for AML
The FDA has placed a partial clinical hold on Gilead's magrolimab, a CD47 candidate for acute myeloid leukemia (AML). Gilead has halted the screening and enrollment of new patients in US trials studying the drug in AML, but patients already enrolled can continue treatment. The hold affects two Phase III studies, ENHANCE-2 and ENHANCE-3, as well as Gilead's expanded access program.